This is a Truvada news story, published by NBC News, that relates primarily to Gilead news.
For more Truvada news, you can click here:
more Truvada newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from NBC News, you can click here:
more news from NBC NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
powerful new HIV. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest lenacapavir news, HIV treatment news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
injectable HIVNBC News
•
81% Informative
Injectable HIV-prevention drug, lenacapavir, is 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people.
The drug's current list price for use as HIV treatment is $ 3,450 per month.
It remains unclear whether Gilead will set a different price for the drug’s use as PrEP.
Two out of 2,180 participants who received lenacapavir contracted HIV during the trial, as did nine out of 1,087 people who got Truvada .
The trial’s blinded phase will now be ended several months early ; participants will be informed of which drug they received and provided the option of receiving either going forward.
Gilead says it's committed to delivering “lenacapavir swiftly, sustainably and in sufficient volumes, if approved, to high-incidence, resource-limited countries.
The company is in “active discussions with the HIV community” about these plans.
VR Score
81
Informative language
81
Neutral language
25
Article tone
formal
Language
English
Language complexity
58
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
14
Source diversity
8
Affiliate links
no affiliate links